102-5 anti-CLPTM1L

**102-5 anti-CLPTM1L** is a monoclonal antibody specifically developed to target cleft lip and palate transmembrane protein 1-like (**CLPTM1L**), a transmembrane protein frequently overexpressed in various cancers, including lung, cervical, pancreatic, ovarian, and oral squamous cell carcinoma[1][3][6]. CLPTM1L plays an **anti-apoptotic role** in tumor cells and is implicated in **chemoresistance**, particularly against agents such as cisplatin[2][3][5]. By binding to CLPTM1L, monoclonal antibodies (like 102-5 anti-CLPTM1L) **suppress cancer cell proliferation and sensitize them to apoptosis**, especially upon chemotherapy. Preclinical studies have shown that monoclonal antibodies against CLPTM1L inhibit cancer growth in vitro and in vivo, primarily by interfering with downstream signaling pathways, notably the PI3K/Akt pathway and the regulation of Bcl-xL, an anti-apoptotic Bcl-2 family member[3]. The antibody is under investigation for its utility as a **chemotherapeutic sensitizer** in multiple malignancies.